← Back to Clinical Trials
Recruiting NCT06291766

NCT06291766 Gestational Diabetes After Gastric Bypass Surgery

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06291766
Status Recruiting
Phase
Sponsor Region Skane
Condition Diabetes, Gestational
Study Type INTERVENTIONAL
Enrollment 120 participants
Start Date 2024-01-01
Primary Completion 2028-12

Eligibility & Interventions

Sex Female only
Min Age 18 Years
Max Age 50 Years
Study Type INTERVENTIONAL
Interventions
FreeStyle Libre 2, continous glucose monitoring

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 120 participants in total. It began in 2024-01-01 with a primary completion date of 2028-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this trial is to compare different means of glucose monitoring in women with gestational diabetes and a history of gastric bypass surgery. The main question it aims to answer is: How does continous glucose monitoring impact the treatment and affect pregnancy outcome in these women. Participants will be randomized to either continous glucose monitoring or regular capillary glucose measurements during the last trimester of their pregnancy. Researchers will compare the glucose measurement outcomes, the glucose lowering treatment given and pregnancy outcomes between groups.

Eligibility Criteria

Inclusion Criteria: * Understands written and spoken Swedish * Previous Gastric Bypass surgery * Diagnosed with gestational diabetes according to our local criteria * Planned follow up at the Specialized Maternity Ward at Skane University Hospital * Understands the use of CGM and is willing to use the system * Have signed informed consent Exclusion Criteria: * Other kinds of bariatric surgery

Contact & Investigator

Central Contact

Ulrika Moll, MD, PhD

✉ ulrika.moll@skane.se

📞 +46733307170

Principal Investigator

Ulrika Moll, MD, PhD

PRINCIPAL INVESTIGATOR

Region Skane

Frequently Asked Questions

Who can join the NCT06291766 clinical trial?

This trial is open to female participants only, aged 18 Years or older, up to 50 Years, studying Diabetes, Gestational. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06291766 currently recruiting?

Yes, NCT06291766 is actively recruiting participants. Contact the research team at ulrika.moll@skane.se for enrollment information.

Where is the NCT06291766 trial being conducted?

This trial is being conducted at Lund, Sweden.

Who is sponsoring the NCT06291766 clinical trial?

NCT06291766 is sponsored by Region Skane. The principal investigator is Ulrika Moll, MD, PhD at Region Skane. The trial plans to enroll 120 participants.

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology